API

Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.

The Synthetic method of Larotrectinib (LOXO-101)

Larotrectinib (LOXO-101) is the first highly potent and selective small molecule ATP competitive inhibitor of all three TRK kinases (TRKA, TRKB, and TRKC) to enter clinical development.

Jan 2,2024  API

Properties and Applications of Silicone Oil

Silicone oils are constituted of a linear chain of siloxane repeating units (–Si–O) and a variety of side chains (radical side groups).

Jan 2,2024  API

Sodium carbonate: Applications and Security

Sodium carbonate is the disodium carbonate salt with an alkaline base. It is widely used in industry.

Jan 2,2024  API

Polyethylene glycol immunogenicity: anti-polyethylene glycol antibody

Polyethylene glycol (PEG) is a flexible, hydrophilic simple polymer that is physically attached to peptides, proteins, nucleic acids, liposomes, and nanoparticles to reduce renal clearance, block anti

Jan 2,2024  API

Sitagliptin: Pharmacological Profile and Therapeutic Efficacy in Type 2 Diabetes

Sitagliptin, a DPP-4 inhibitor, effectively improves glycaemic control in T2D. Rapid absorption, renal elimination, and proven efficacy as monotherapy therapy demonstrate its clinical benefits.

Jan 2,2024  API

Tert-Butyl methyl ether:Uses and Polarity

Tert-Butyl methyl ether (MTBE) has low solubility and is a non-polar solvent. It has a polarity index of 2.5, a boiling point of 55.3°C, a viscosity of 0.27 (20°C), a refractive index of 1.369, and a

Dec 29,2023  API

D-Galactose: Versatile Sources, Applications, and Considerations for Toxicity

D-Galactose can be obtained from terrestrial plants, and macroalgae and has versatile applications, but its toxicity should be considered in metabolic disorders and excessive intake.

Dec 29,2023  API

Iron oxide nanoparticles in photothermal therapy

Iron oxide nanoparticles are promising for cancer treatment via photothermal therapy due to their unique properties, biocompatibility, and ease of modification.

Dec 29,2023  API

How to synthesize Glasdegib?

Glasdegib was approved in 2018 for the treatment of newly diagnosed acute myeloid leukemia (AML) patients at least 75 years of age who are not appropriate candidates for intensive induction chemothera

Dec 28,2023  API

The Pharmacodynamics and Synthetic method of Gilteritinib

Gilteritinib, an oral inhibitor of FMS‐like tyrosine kinase 3 (FLT3), is a standard treatment for FLT3‐mutated acute myeloid leukemia.

Dec 28,2023  API
Prev12345678910...Next>  Go to Page